UBS Group’s C4 Therapeutics CCCC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $818K | Sell |
572,026
-300,744
| -34% | -$430K | ﹤0.01% | 4497 |
|
|
2025
Q1 | $1.4M | Buy |
872,770
+114,918
| +15% | +$184K | ﹤0.01% | 3951 |
|
|
2024
Q4 | $2.73M | Buy |
757,852
+423,771
| +127% | +$1.53M | ﹤0.01% | 3466 |
|
|
2024
Q3 | $1.9M | Sell |
334,081
-70,037
| -17% | -$399K | ﹤0.01% | 3069 |
|
|
2024
Q2 | $1.87M | Sell |
404,118
-292,559
| -42% | -$1.35M | ﹤0.01% | 2907 |
|
|
2024
Q1 | $5.69M | Buy |
696,677
+418,302
| +150% | +$3.42M | ﹤0.01% | 2073 |
|
|
2023
Q4 | $1.57M | Sell |
278,375
-43,234
| -13% | -$244K | ﹤0.01% | 3056 |
|
|
2023
Q3 | $598K | Buy |
321,609
+51,807
| +19% | +$96.4K | ﹤0.01% | 3484 |
|
|
2023
Q2 | $742K | Buy |
269,802
+107,152
| +66% | +$295K | ﹤0.01% | 3527 |
|
|
2023
Q1 | $511K | Sell |
162,650
-107,570
| -40% | -$338K | ﹤0.01% | 3687 |
|
|
2022
Q4 | $1.59M | Sell |
270,220
-46,825
| -15% | -$276K | ﹤0.01% | 2745 |
|
|
2022
Q3 | $2.78M | Sell |
317,045
-30,141
| -9% | -$264K | ﹤0.01% | 2118 |
|
|
2022
Q2 | $2.62M | Buy |
347,186
+17,608
| +5% | +$133K | ﹤0.01% | 2208 |
|
|
2022
Q1 | $8M | Sell |
329,578
-13,220
| -4% | -$321K | ﹤0.01% | 1600 |
|
|
2021
Q4 | $11M | Sell |
342,798
-74,555
| -18% | -$2.4M | ﹤0.01% | 1485 |
|
|
2021
Q3 | $18.6M | Buy |
417,353
+15,980
| +4% | +$714K | 0.01% | 1155 |
|
|
2021
Q2 | $15.2M | Buy |
401,373
+138,935
| +53% | +$5.26M | ﹤0.01% | 1261 |
|
|
2021
Q1 | $9.71M | Buy |
262,438
+161,722
| +161% | +$5.98M | ﹤0.01% | 1465 |
|
|
2020
Q4 | $3.34M | Buy |
+100,716
| New | +$3.34M | ﹤0.01% | 2197 |
|